238 related articles for article (PubMed ID: 19415121)
1. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Rosell R; Perez-Roca L; Sanchez JJ; Cobo M; Moran T; Chaib I; Provencio M; Domine M; Sala MA; Jimenez U; Diz P; Barneto I; Macias JA; de Las Peñas R; Catot S; Isla D; Sanchez JM; Ibeas R; Lopez-Vivanco G; Oramas J; Mendez P; Reguart N; Blanco R; Taron M
PLoS One; 2009; 4(5):e5133. PubMed ID: 19415121
[TBL] [Abstract][Full Text] [Related]
2. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Moran T; Wei J; Cobo M; Qian X; Domine M; Zou Z; Bover I; Wang L; Provencio M; Yu L; Chaib I; You C; Massuti B; Song Y; Vergnenegre A; Lu H; Lopez-Vivanco G; Hu W; Robinet G; Yan J; Insa A; Xu X; Majem M; Chen X; de Las Peñas R; Karachaliou N; Sala MA; Wu Q; Isla D; Zhou Y; Baize N; Zhang F; Garde J; Germonpre P; Rauh S; ALHusaini H; Sanchez-Ronco M; Drozdowskyj A; Sanchez JJ; Camps C; Liu B; Rosell R; ; Colinet B; De Grève J; Germonpré P; Chen H; Chen X; Du J; Gao Y; Hu J; Hu W; Kong W; Li L; Li R; Li X; Liu B; Liu J; Lu H; Qian X; Ren W; Song Y; Wang L; Wei J; Wen L; Wu Q; Xiao X; Xu X; Yan J; Yang J; Yang M; Yang Y; Yin J; You C; Yu L; Yue X; Zhang F; Zhang J; Zhou Y; Zhu L; Zou Z; Baize N; Bombaron P; Chouaid C; Dansin E; Fournel P; Fraboulet G; Gervais R; Hominal S; Kahlout S; Lecaer H; Lena H; LeTreut J; Locher C; Molinier O; Monnet I; Oliviero G; Robinet G; Schoot R; Thomas P; Vergnènegre A; Berchem G; Rauh S; Al Husaini H; Aparisi F; Arriola E; Ballesteros I; Barneto I; Bernabé R; Blasco A; Bosch-Barrera J; Bover I; Calvo de Juan V; Camps C; Carcereny E; Catot S; Cobo M; De Las Peñas R; Dómine M; Felip E; García-Campelo MR; García-Girón C; García-Gómez R; Garcia-Sevila R; Garde J; Gasco A; Gil J; González-Larriba JL; Hernando-Polo S; Jantus E; Insa A; Isla D; Jiménez B; Lianes P; López-López R; López-Martín A; López-Vivanco G; Macias JA; Majem M; Marti-Ciriquian JL; Massuti B; Montoyo R; Morales-Espinosa D; Morán T; Moreno MA; Pallares C; Parera M; Pérez-Carrión R; Porta R; Provencio M; Reguart N; Rosell R; Rosillo F; Sala MA; Sanchez JM; Sullivan I; Terrasa J; Trigo JM; Valdivia J; Viñolas N; Viteri S; Botia-Castillo M; Mate JL; Perez-Cano M; Ramirez JL; Sanchez-Rodriguez B; Taron M; Tierno-Garcia M; Mijangos E; Ocaña J; Pereira E; Shao J; Sun X; O'Brate R
Ann Oncol; 2014 Nov; 25(11):2147-2155. PubMed ID: 25164908
[TBL] [Abstract][Full Text] [Related]
3. [Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Wei J; Qian XP; Zou ZY; Wang LF; Yu LX; You CW; Song Y; Lu HY; Hu WJ; Yan J; Xu XX; Chen XF; Li XY; Wu QF; Zhou Y; Zhang FL; Liu BR
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):868-873. PubMed ID: 27998448
[No Abstract] [Full Text] [Related]
4. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
6. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
[TBL] [Abstract][Full Text] [Related]
7. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
8. Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Rosell R; Moran T; Viteri S; Carcereny E; Gasco A; Quiroga V; Wei J; Camps C; Massuti B
Expert Opin Pharmacother; 2010 Jul; 11(10):1683-93. PubMed ID: 20486827
[TBL] [Abstract][Full Text] [Related]
9. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
10. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
11. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
[TBL] [Abstract][Full Text] [Related]
12. Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).
Wei J; Moran T; Zou Z; Qian X; Wang L; Camps C; Hu W; Chaib I; Sanchez B; Xu L; Karachaliou N; Sanchez-Ronco M; Liu B; Rosell R
Transl Lung Cancer Res; 2013 Jun; 2(3):180-8. PubMed ID: 25806231
[TBL] [Abstract][Full Text] [Related]
13. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
Carcereny E; Ramirez JL; Sanchez-Ronco M; Isla D; Cobo M; Moran T; de Aguirre I; Okamoto T; Wei J; Provencio M; Lopez-Vivanco G; Camps C; Domine M; Alberola V; Sanchez JM; Massuti B; Mendez P; Taron M; Rosell R
Lung Cancer; 2010 Jun; 68(3):491-7. PubMed ID: 19733931
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing for chemotherapy in non-small cell lung cancer.
Rosell R; Taron M; Alberola V; Massuti B; Felip E
Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Wu YL; Zhou C; Lu S; Qin S; Pan H; Wu G; Cheng Y; Liu X; Han B; Zhu Y; Zhong Z; Huang C; Chen L; Liang H; Li E; Jiang G
Lung Cancer; 2019 Apr; 130():18-24. PubMed ID: 30885342
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T; Morita S; Yatabe Y; Negoro S; Okamoto I; Tsurutani J; Seto T; Satouchi M; Tada H; Hirashima T; Asami K; Katakami N; Takada M; Yoshioka H; Shibata K; Kudoh S; Shimizu E; Saito H; Toyooka S; Nakagawa K; Fukuoka M;
Lancet Oncol; 2010 Feb; 11(2):121-8. PubMed ID: 20022809
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
18. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
Paz-Ares L; Socinski MA; Shahidi J; Hozak RR; Soldatenkova V; Kurek R; Varella-Garcia M; Thatcher N; Hirsch FR
Ann Oncol; 2016 Aug; 27(8):1573-9. PubMed ID: 27207107
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
[TBL] [Abstract][Full Text] [Related]
20. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
